Three biotechnology companies sued Columbia University on Tuesday, alleging that the school has illegally extended the life of a lucrative patent for gene-splicing technology. Biogen Inc., Genzyme Corp., and Abbott Laboratories filed the lawsuit in U.S. District Court in Boston, claiming they have collectively paid tens of millions of dollars in royalties to Columbia for using the technology, and should not have to pay more.
July 17, 2003 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
Presented by BigVoodoo
This conference aims to help insurers and litigators better manage complex claims and litigation.
Recognizing innovation in the legal technology sector for working on precedent-setting, game-changing projects and initiatives.
Legalweek New York explores Business and Regulatory Trends, Technology and Talent drivers impacting law firms.
Our client, a thriving personal injury firm known for its commitment to compassionate client care is seeking an attorney with 5+ years of ex...
McCarter and English s Chambers-ranked Government Contracts group is seeking an experienced, diligent, and proactive government contracts as...
The Court of Appeal, First Appellate District in San Francisco is accepting applications for a central staff attorney vacancy. A regular ful...